Skip to content

Study · Case report or series · n = 1 · 1987

1 result

Intraventricular somatostatin-14, arginine vasopressin, and oxytocin: analgesic effect in a patient with intractable cancer pain.

Madrazo I, Franco-Bourland RE, León-Meza VM, Mena I

Applied neurophysiology1 Jan 1987Cited by 71 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In one terminally ill cancer patient with intractable thoracic pain, intraventricular oxytocin reduced pain by 88% for 77 min.

    In plain wordsIn one patient with severe cancer pain, oxytocin given into the brain ventricles reduced pain by 88% for 77 minutes.

    Peptide
    Oxytocin
    Outcome
    DecreasePain reduction after intraventricular oxytocin
    Study

    n = 1

    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated · intraventricularAs given in this study (human).

    Measurements

    pain reduction
    88%
    oxytocin
    duration of pain reduction
    77 min
    oxytocin

    Source sentences

    Summary
    SOM-14 reduced pain by 90% for 48 min; AVP reduced pain by 95% for 75 min, and OT reduced pain by 88% for 77 min.
    1 context sentence
    Summary · context
    The analgesic effect of intraventricular somatostatin-14 (SOM-14), arginine vasopressin (AVP), and oxytocin (OT) were tested in one terminally ill cancer patient with a diffuse mesothelioma suffering intractable continuous and incapacitating thoracic pain.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 ongoing · 1 stopped early · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 2NCT06483659

Intravenous Oxytocin for Post Operative Pain After Minimally Invasive Hysterectomy

Brigham and Women's Hospitaln = 1521 Jun 2025 to est. 30 Jun 2028

Postoperative Pain

Trial pageClinicalTrials.govUpdated 13 Aug 2026
WithdrawnPhase 4NCT05608070

IV Oxytocin for Post Operative Pain After Minimally Invasive Hysterectomy

Beth Israel Deaconess Medical Centern = 01 Jun 2023 to est. Jun 2025

Pain, Postoperative · Analgesia · Postoperative Pain · Pain, Post Operative · Oxytocin

Trial pageClinicalTrials.govUpdated 14 Aug 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 20:03 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:53 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.